Metabolism

Mounjaro vs Zepbound: Same Drug, Different Prescription

Medically reviewed by Medical Advisory Board Last reviewed 2026-06-15

Both are tirzepatide — what actually changes between the two brands

Mounjaro and Zepbound are the same drug (tirzepatide) made by the same manufacturer (Eli Lilly). The difference is FDA approval: Mounjaro is approved for Type 2 diabetes; Zepbound is approved for obesity and weight management. This guide explains what actually changes — insurance, access, labeling — and how to get the right one for your situation.

Mounjaro vs Zepbound is less a clinical question than an insurance and access question. Both contain tirzepatide — the same active ingredient, the same weekly injection, the same dose options (2.5 mg to 15 mg). Eli Lilly manufactures both under different brand names because the FDA approval pathways for diabetes and obesity are separate.

For the clinical comparison of tirzepatide versus its GLP-1 competitor semaglutide, see Ozempic vs Mounjaro and Wegovy vs Zepbound. For the full GLP-1 drug class picture, visit our GLP-1 guide.

Mounjaro vs Zepbound: What Actually Differs

FactorMounjaroZepbound
Active ingredientTirzepatideTirzepatide
ManufacturerEli LillyEli Lilly
FDA approvalType 2 diabetes (May 2022)Obesity / weight management (Nov 2023)
Dose range2.5–15 mg weekly2.5–15 mg weekly
DeliveryAutoinjector pen, weeklyAutoinjector pen, weekly
Insurance coverage pathDiabetes benefit (broader coverage)Obesity/weight-loss benefit (more variable)
List price~$1,100/month~$1,060/month
Manufacturer savings programsLilly Cares / Mounjaro Savings CardZepbound Savings Card (as low as $25/mo for eligible patients)

Why There Are Two Brand Names for the Same Drug

The FDA approves drugs for specific indications. A drug approved for Type 2 diabetes and one approved for obesity go through different clinical trial programs, even if the molecule is identical. Pharmaceutical companies file separate New Drug Applications for each indication — and often use different brand names for commercial and insurance reasons.

In practice, some people who do not have diabetes have obtained Mounjaro off-label for weight loss (when Zepbound was unavailable or not yet covered), and vice versa. The FDA does not prohibit off-label prescribing, but insurance typically covers only the approved indication for each brand.

Which One to Ask For

If you have Type 2 diabetes: Mounjaro is the on-label choice and will have the clearest insurance path through your diabetes benefit.
If you are using it for weight loss without diabetes: Zepbound is the on-label choice and is what most obesity medicine specialists will prescribe. Its Savings Card program can make it substantially cheaper for commercially insured patients.
If your insurer covers one but not the other: Your doctor can prescribe either; discuss the off-label path and prior authorization requirements with your plan.

The Verdict

Mounjaro and Zepbound are clinically identical. The right one is whichever your insurer covers better for your indication. If you have diabetes, start with Mounjaro. If you are treating obesity, Zepbound is the intended product and its savings programs are currently generous. Take our free metabolic assessment to clarify your situation, or book a consultation with a clinician who can navigate the prescription path for you.

Frequently Asked Questions

Is Mounjaro the same as Zepbound?

Yes — both contain tirzepatide, the same active ingredient, at the same doses (2.5–15 mg weekly). They are manufactured by Eli Lilly. The only difference is their FDA-approved indication: Mounjaro is approved for Type 2 diabetes, Zepbound is approved for obesity and weight management. The autoinjector pens and formulations are functionally the same.

Can I use Mounjaro for weight loss instead of Zepbound?

Doctors can prescribe Mounjaro off-label for weight loss — the active drug is identical. However, your insurance is most likely to cover Mounjaro through the diabetes benefit and Zepbound through the obesity/weight-loss benefit. Using Mounjaro off-label for weight management typically means paying out of pocket or navigating prior authorization, since the on-label weight-loss product is Zepbound.

Is Zepbound cheaper than Mounjaro?

Their list prices are similar (~$1,060 vs ~$1,100/month). The meaningful cost difference comes from savings programs: Lilly's Zepbound Savings Card has offered as low as $25/month for eligible commercially insured patients in its launch period. Mounjaro also has a savings card. Neither is covered by Medicare Part D for weight loss only (as of early 2026). Always verify current programs with your pharmacist.

Why did my doctor prescribe Mounjaro when Zepbound exists?

Usually for one of three reasons: (1) you have Type 2 diabetes, so Mounjaro is the on-label choice; (2) your insurance covers Mounjaro on its diabetes formulary but not Zepbound on its weight-loss formulary; or (3) Zepbound was in short supply at your pharmacy. Since the drug itself is identical, the clinical effect is the same either way.

Topic updates

Get the weekly metabolic health roundup

Insulin resistance, blood sugar, visceral fat, GLP-1 plateaus, metabolic syndrome, and weight-loss physiology.

No spam. Unsubscribe anytime.

M
Medically Reviewed
Medical Advisory Board
Board-Certified Physician
Last reviewed: 2026-06-15
Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making changes to your health regimen.

Check Where You Stand

Take our free health assessment to understand your metabolic, hormonal, and recovery risk factors — and get personalized recommendations.

Take the Free Assessment →

Free · Takes 5 minutes · Instant results

Continue Reading

← Back to Metabolic Health

Understand your health — on your terms

Use our free tools and evidence-based guides to make smarter decisions about your metabolism, hormones, and recovery.

Take the Free Assessment →